Tumor Stroma Infiltrating T Cells Predict the Efficacy of Anti-CTLA-4 Antibody in NSCLC
Despite the increased risk of irAEs, patients with high stromal infiltration of CD8+ and FOXP3+ T cells may derive meaningful clinical benefit from anti-CTLA-4 antibody therapy. Assessing these immune parameters could aid in appropriate patient selection and contribute to optimizing therapeutic outcomes.
Authors
- Osamu Honjo
- Naoki Shijubo
- Hirofumi Chiba (ORCID: https://orcid.org/0000-0002-7033-3084)
- Hiroyuki Koba
- Toyohiro Saikai
- Yoshihiko Hirohashi (ORCID: https://orcid.org/0000-0002-0608-3914)
- Toshihiko Torigoe (ORCID: https://orcid.org/0000-0002-9463-5917)
- Astushi Saito
- Akihisa Fujita
- YASUHITO HONDA
- HIROTSUGU TAKABATAKE
- TOSHIYUKI SUMI
- HIROSHI SAIJO
Institutions
- Sapporo Medical University (JP)
- Sapporo Minami Hospital (JP)
- Hakodate National Hospital (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2025-12-30
- DOI
- https://doi.org/10.21873/anticanres.17944
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00